kabutan

BrightPath Biotherapeutics, First Half Net Income Loss Narrows, Jul-Sep Net Income Loss Widens

Fri Nov 14, 2025 3:32 pm JST Earnings

4594 BrightPath Biotherapeutics Co., Ltd. 【J-GAAP】

Earnings Report

BrightPath Biotherapeutics Co., Ltd. <4594> [TSE Growth] announced its financial results after the market closed on November 14th (15:32). The net loss (non-consolidated) for the cumulative second quarter of the fiscal year ending March 2026 (April to September) was a reduced loss of 462 million yen (compared to a loss of 538 million yen in the same period last year).

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the net loss for the October to March period (second half) is expected to expand to a loss of 704 million yen (compared to a loss of 613 million yen in the same period last year).

In the most recent three-month period, from July to September (2Q), the net loss expanded to loss of 221 million yen (compared to a loss of 208 million yen in the same period last year).

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2023 0 -550 -551 -553 -8.8 ー Nov 10, 2023 J-GAAP
Apr - Sep, 2024 0 -542 -537 -538 -7.1 ー Nov 8, 2024 J-GAAP
Apr - Sep, 2025 0 -464 -460 -462 -4.5 ー Nov 14, 2025 J-GAAP
YoY － +14.4% +14.3% +14.1% +36.3%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 Guidance ー ー ー ー － 0 May 9, 2025 J-GAAP
Apr - Sep, 2025 Results 0 -464 -460 -462 -4.5 0 Nov 14, 2025 J-GAAP
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 1 -618 -610 -613 -7.5 0 May 9, 2025 J-GAAP
Oct - Mar, 2025 Guidance 0 -718 -704 -704 -6.3 0 Nov 14, 2025 J-GAAP
YoY － -16.2% -15.4% -14.8% +16.0%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 0 -1,155 -1,158 -1,168 -18.2 0 May 10, 2024 J-GAAP
Mar, 2025 1 -1,160 -1,147 -1,151 -14.1 0 May 9, 2025 J-GAAP
Mar, 2026 Guidance 0 -1,182 -1,164 -1,166 -10.5 0 May 9, 2025 J-GAAP
YoY － -1.9% -1.5% -1.3% +25.8%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2024 0 -216 -208 -208 -2.8 -Inf Nov 8, 2024 J-GAAP
Oct - Dec, 2024 0 -273 -275 -277 -3.5 -Inf Feb 14, 2025 J-GAAP
Jan - Mar, 2025 1 -345 -335 -336 -4.1 -34,500.0 May 9, 2025 J-GAAP
Apr - Jun, 2025 0 -245 -240 -241 -2.6 -Inf Aug 8, 2025 J-GAAP
Jul - Sep, 2025 0 -219 -220 -221 -2.2 -Inf Nov 14, 2025 J-GAAP
YoY － -1.4% -5.8% -6.3% +21.1%

Related Articles